Bariatric Surgery for the Treatment of Type 2 Diabetes - Clinical Effects and Underlying Mechanisms (Bariglykos)
Primary Purpose
Type 2 Diabetes Mellitus, Obesity
Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Laparoscopic Gastric Bypass
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Males and females aged 18-60 years
- Type 2 Diabetes Mellitus with duration of no more than 10 years, treated with 0-3 oral anti-diabetic drugs or Glucagon-like peptide-1 (GLP-1) analog.
Exclusion Criteria:
- Pregnant or planning to be pregnant during the study.
- Known or suspected history of significant drug abuse.
- History of alcohol abuse or excessive intake of alcohol as judged by investigator.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator
- Sleep apnea
- Any previous serious cardiovascular event, stroke , acute myocardial infarction.
- Diabetes complications : proliferative retinopathy, maculopathy, chronic renal failure stadium 3 with an Estimated Glomerular Filtration Rate (eGFR) <60, foot ulcers, symptomatic neuropathy
- Medications within 3 months : Insulin, Thiazolidinediones
- Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study and /or for the patients safety
- Judgment by the investigator that the subject should not participate in the study if considers subject unlikely to comply with study procedures, restrictions and requirements.
Sites / Locations
- Uppsala University, Department of Medical Sciences, Clinical diabetology and metabolism
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Other
Arm Label
Control Group
Surgery Group
Arm Description
The patients in this group will undergo Laparoscopic Gastric Bypass surgery
Outcomes
Primary Outcome Measures
Change from Baseline of Glucose Turnover
Change from Baseline of homeostatic model assessment (HOMA) for insulin resistance
Change from Baseline of beta cell function
Secondary Outcome Measures
Change from Baseline of Glucose Turnover
Change from Baseline of Glucose Turnover
Change from Baseline of homeostatic model assessment (HOMA) for insulin resistance
Change from Baseline of homeostatic model assessment (HOMA) for insulin resistance
Change from Baseline of beta cell function
Change from Baseline of beta cell function
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02729246
Brief Title
Bariatric Surgery for the Treatment of Type 2 Diabetes - Clinical Effects and Underlying Mechanisms
Acronym
Bariglykos
Official Title
Bariatric Surgery for the Treatment of Type 2 Diabetes - Clinical Effects and Underlying Mechanisms
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
October 2014 (undefined)
Primary Completion Date
December 30, 2019 (Actual)
Study Completion Date
February 10, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Uppsala University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main purpose of this project is to further explore the metabolic effects and the mechanisms underlying the improvement in glucose homeostasis following bariatric surgery. The project will involve both prevention and treatment of Type 2 Diabetes (T2D), and both pre-diabetic as well as diabetic subjects with obesity will be included. This part of the project focuses on patients with manifest T2D and they will be assigned to surgical and non-surgical intervention, respectively, in a strictly controlled and randomized manner.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Control Group
Arm Type
No Intervention
Arm Title
Surgery Group
Arm Type
Other
Arm Description
The patients in this group will undergo Laparoscopic Gastric Bypass surgery
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Gastric Bypass
Primary Outcome Measure Information:
Title
Change from Baseline of Glucose Turnover
Time Frame
1 month after surgery
Title
Change from Baseline of homeostatic model assessment (HOMA) for insulin resistance
Time Frame
1 month after surgery
Title
Change from Baseline of beta cell function
Time Frame
1 month after surgery
Secondary Outcome Measure Information:
Title
Change from Baseline of Glucose Turnover
Time Frame
6 months after surgery
Title
Change from Baseline of Glucose Turnover
Time Frame
24 months after surgery
Title
Change from Baseline of homeostatic model assessment (HOMA) for insulin resistance
Time Frame
6 months after surgery
Title
Change from Baseline of homeostatic model assessment (HOMA) for insulin resistance
Time Frame
24 months after surgery
Title
Change from Baseline of beta cell function
Time Frame
6 months after surgery
Title
Change from Baseline of beta cell function
Time Frame
24 months after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and females aged 18-60 years
Type 2 Diabetes Mellitus with duration of no more than 10 years, treated with 0-3 oral anti-diabetic drugs or Glucagon-like peptide-1 (GLP-1) analog.
Exclusion Criteria:
Pregnant or planning to be pregnant during the study.
Known or suspected history of significant drug abuse.
History of alcohol abuse or excessive intake of alcohol as judged by investigator.
History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator
Sleep apnea
Any previous serious cardiovascular event, stroke , acute myocardial infarction.
Diabetes complications : proliferative retinopathy, maculopathy, chronic renal failure stadium 3 with an Estimated Glomerular Filtration Rate (eGFR) <60, foot ulcers, symptomatic neuropathy
Medications within 3 months : Insulin, Thiazolidinediones
Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study and /or for the patients safety
Judgment by the investigator that the subject should not participate in the study if considers subject unlikely to comply with study procedures, restrictions and requirements.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Eriksson, Professor
Organizational Affiliation
Department of Medical Sciences, Clinical diabetology and metabolism
Official's Role
Principal Investigator
Facility Information:
Facility Name
Uppsala University, Department of Medical Sciences, Clinical diabetology and metabolism
City
Uppsala
Country
Sweden
12. IPD Sharing Statement
Citations:
PubMed Identifier
34086911
Citation
Almby KE, Katsogiannos P, Pereira MJ, Karlsson FA, Sundbom M, Wiklund U, Kamble PG, Eriksson JW. Time Course of Metabolic, Neuroendocrine, and Adipose Effects During 2 Years of Follow-up After Gastric Bypass in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4049-e4061. doi: 10.1210/clinem/dgab398.
Results Reference
derived
PubMed Identifier
33062061
Citation
Katsogiannos P, Randell E, Sundbom M, Rosenblad A, Eriksson JW, Leksell J. Quality of life after gastric bypass surgery in patients with type 2 diabetes: patients' experiences during 2 years of follow-up. Diabetol Metab Syndr. 2020 Oct 12;12:90. doi: 10.1186/s13098-020-00597-1. eCollection 2020.
Results Reference
derived
PubMed Identifier
30689903
Citation
Katsogiannos P, Kamble PG, Boersma GJ, Karlsson FA, Lundkvist P, Sundbom M, Pereira MJ, Eriksson JW. Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2601-2613. doi: 10.1210/jc.2018-02165.
Results Reference
derived
Learn more about this trial
Bariatric Surgery for the Treatment of Type 2 Diabetes - Clinical Effects and Underlying Mechanisms
We'll reach out to this number within 24 hrs